Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesGastroenterologyPriority Health GERD Barrett's Coverage Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy NO. 91483

    Gastroesophageal Reflux Disease (GERD) and Barrett's Esophagus

    Customize your policy alerts

    Sign up for priority health Policy NO. 91483 alerts

    Get alerted when Policy NO. 91483 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, coverage limitations, and investigational exclusions for diagnosis and treatment of gastroesophageal reflux disease (GERD) and Barrett's esophagus for Priority Health members.

    Policy Summary
    Payerpriority health
    PolicyGastroesophageal Reflux Disease (GERD) and Barrett's Esophagus
    Policy CodePolicy NO. 91483
    Change TypeMinor — added Medicare CLFS note
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization and document objective testing (endoscopy, ambulatory pH off medication, and esophageal manometry) plus prior medical therapy when requesting coverage for device- or procedure-based GERD interventions.
    SourceLink
    POLICY UPDATE CHANGES

    Added reference in Section II (Medicare section) to explicitly note that some advanced diagnostic laboratory tests may meet criteria for designation as Advanced Diagnostic Laboratory Tests under the Medicare Clinical Laboratory Fee Schedule (CLFS).

    6+device/technique categories
    18-74age range (LINX)
    ≤35BMI threshold (LINX)
    ≤2/ <3cmhiatal hernia limits
    ≥6moPPI duration referenced
    Multipleprocedures not covered

    Coverage Criteria and Medical Necessity

    Transoral Incisionless Fundoplication (TIF/cTIF) — Medically Necessary

    Covered when ALL of the following are met:

    TIF eligibility: 1) Normal esophageal motility documented by manometry or video esophagogram; AND 2) One of: anatomic disruption of the gastroesophageal (GE) flap valve, persistent GERD symptoms despite proton pump inhibitor (PPI) therapy for at least 6 months, OR objective evidence of reflux while on PPI (erosive esophagitis, abnormal ambulatory pH, or biopsy-confirmed reflux esophagitis); AND 3) None of the listed contraindications (see exclusions).

    Contraindications include active esophago-gastro-duodenal ulcer disease; BMI ≥ 35; hiatal hernia > 2 cm; esophagitis grade D or Barrett's esophagitis; prior relevant surgeries; portal hypertension/varices; motility disorders; pregnancy; and other conditions listed in policy.

    Stretta Radiofrequency Procedure — Medically Necessary

    Covered when ALL of the following are met (1 or 2, and 3):

    Entry criteria (path 1): Member must have daily GERD > 6 months as evidenced by one of: pathologic pH study performed off medication, upper endoscopy showing Los Angeles Grade A or B esophagitis, abnormal reflux on impedance testing, or biopsy-confirmed reflux esophagitis; AND esophageal manometry demonstrating normal peristalsis and normal sphincter relaxation; AND symptoms refractory to daily appropriate-dose antisecretory therapy.
    Policy Summary
    Payerpriority health
    PolicyGastroesophageal Reflux Disease (GERD) and Barrett's Esophagus
    Policy CodePolicy NO. 91483
    Change TypeMinor — added Medicare CLFS note
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization and document objective testing (endoscopy, ambulatory pH off medication, and esophageal manometry) plus prior medical therapy when requesting coverage for device- or procedure-based GERD interventions.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding and BillingProvider Responsibilities, Prior Authorization, and DocumentationDefinitions and Device/Procedure DescriptionsPolicy Revision History
    Entry criteria (path 2): Alternatively, member has reflux-related aspiration pneumonia or laryngopharyngeal reflux.
    Exclusion criteria: Member must NOT have any of: ASA IV classification; Barrett's esophagus; Esophagitis grade C or D; hiatal hernia >2 cm; autoimmune or collagen vascular disorders; coagulation disorder or current anticoagulant therapy; life‑threatening disorder with limited life expectancy; achalasia; current pregnancy; and other exclusions listed in policy.

    Presence of any exclusion criterion precludes coverage.

    Magnetic Sphincter Augmentation (LINX/MSA) — Medically Necessary

    Covered when ALL of the following are met:

    LINX eligibility: 1) Age 18–74 years; 2) Body mass index ≤ 35; 3) Documented typical GERD symptoms (regurgitation or heartburn) for >6 months; 4) Refractory to ideal medical management (e.g., requires twice-daily PPI or other anti-reflux therapy and lifestyle changes discussed); 5) Hiatal hernia < 3 cm by endoscopy; 6) Total distal ambulatory esophageal pH <4 for ≥4.5% of the time with discontinuation of GERD medications for at least 7 days prior to testing; 7) Distal esophageal motility within normal range by conventional manometry or high-resolution manometry; 8) Symptomatic improvement on PPI demonstrated by GERD-HRQL score criteria or ≥6-point improvement on/off PPI; AND 9) None of the listed contraindications (including current electrical or metallic implants, scleroderma, major motility disorders, significant dysphagia, esophagitis grade C/D, prior anti-reflux surgery, life expectancy <3 years, pregnancy/breastfeeding, or metal allergies).

    Multiple device- and patient-specific exclusions apply and should be reviewed prior to authorization.

    Endoscopic Mucosal Resection/Thermal Ablation for Barrett's Esophagus — Medically Necessary

    Covered when ALL of the following are met:

    BE ablation/resection: Presence of dysplastic Barrett's esophagus and/or early esophageal adenocarcinoma; AND use of endoscopic mucosal resection (EMR) and/or thermal ablation modalities (e.g., radiofrequency ablation/Barrx) or photodynamic therapy is for treatment of dysplastic BE or early EAC.

    These modalities are not supported for non-dysplastic Barrett's esophagus per policy.

    Device/Endoscopic Plication — Candidate Criteria

    Covered when ALL of the following are met (per trial eligibility and device intent):

    PPI-refractory symptomatic GERD: Persistent GERD symptoms despite optimized pharmacologic therapy (e.g., > 6 months of PPI therapy as in GERDx study)> 6 months

    Based on trial entry criteria and device-specific studies.

    Anatomic suitability: Hiatal hernia size ≤ 2 cm and appropriate gastroesophageal valve/Hill grade per device-specific requirements (e.g., TIF/GERDx platform specifications).≤ 2 cm

    Device trials and descriptions specify hiatal hernia limits.

    Objective testing: Pathologic acid exposure or other objective confirmation of reflux (e.g., pH/DeMeester) when available to support indication.Per investigator protocol/DeMeester thresholds

    Many device studies required objective reflux evidence.

    Investigational / Not Medically Necessary Procedures

    Not covered / Investigational when ANY of the following apply:

    Procedures lacking guideline endorsement or sufficient evidence: Antireflux mucosal interventions (ARMS/ARMA) remain investigational without guideline endorsement and have heterogeneous evidence with higher procedural risks (e.g., stricture, bleeding, perforation).

    Systematic reviews and meta-analyses report higher morbidity for ARMS vs Stretta.

    Polymer injection/implantation techniques with inadequate safety data: Polymer injection/implantation techniques (e.g., Enteryx, Gatekeeper, PMMA beads, Duraspheres) lack sufficient evidence and have documented safety concerns (including recalled Enteryx) and are considered investigational/not covered.

    FDA recall history and absence of guideline support cited in policy.

    WATS-3D — Adjunctive vs Standalone Stance

    Adjunctive diagnostic sampling (WATS-3D):

    Adjunctive use: WATS-3D may be used adjunctively to standard forceps (Seattle protocol) biopsies to increase detection yield of Barrett's esophagus and dysplasia, though the long-term outcome implications of WATS-positive/forceps-biopsy-negative findings remain uncertain.

    Multiple studies show incremental detection; guideline recommendations vary (ASGE conditional, AGA supportive as adjunct).

    Stand-alone use: WATS-3D used as a standalone replacement for standard forceps biopsies is not consistently supported by the evidence and is not endorsed as a replacement sampling strategy.

    Randomized trials show WATS alone did not significantly outperform forceps biopsy as a standalone technique.

    Covered endoscopic procedures for GERD

    The following procedures are covered only when performed for the gastroesophageal reflux disease diagnoses listed in the policy:

    Covered CPTs for GERD: CPT 43210 (EGD with esophagogastric fundoplasty when billed for EsophyX System) and CPT 43257 (EGD with delivery of thermal energy to LES/gastric cardia when billed for Stretta System) are covered only for the specified GERD ICD-10 diagnoses in this policy.

    Billing must reflect an indicated GERD diagnosis per the policy.

    Not medically necessary procedures for GERD

    The following procedures are designated not medically necessary for the GERD diagnoses above:

    Not medically necessary CPTs: CPTs 43211, 43229, 43254, and 43270 (esophagoscopy/EGD with EMR or ablation codes listed) are considered not medically necessary when billed for the GERD diagnoses enumerated in this policy.

    Sphincter augmentation device placement/removal

    Placement and removal: CPT 43284 (laparoscopic placement of esophageal sphincter augmentation device) requires prior authorization; CPT 43285 (removal of esophageal sphincter augmentation device) does not require prior authorization.

    43284 coverage contingent on meeting policy criteria and authorization requirements.

    Prior authorization-required services — Covered when criteria and authorization requirements are met

    Covered when criteria and authorization requirements are met

    Sphincter augmentation placement: CPT 43284 is covered but requires prior authorization before the procedure is approved for coverage consideration.prior authorization

    Includes cruroplasty when performed.

    Molecular tests requiring prior auth: Molecular/algorithmic pathology U-codes 0114U, 0398U, and 0506U require prior authorization before coverage consideration; note that 0108U (TissueCypher) is described as Medicare-covered only.prior authorization

    Providers must submit medical necessity documentation per Priority Health procedures.

    Explicit not-covered procedures

    Not covered procedures

    Not covered endoscopic/surgical procedures: Procedures listed (CPTs 43201, 43206, 43210 when billed for specific excluded devices/systems, 43229, 43236, 43252, 43254) are explicitly not covered when billed for the specified GERD/Barrett's Esophagus treatments or technologies described in the policy.N/A

    Includes various implant, injection, ablation, endomicroscopy and endoscopic mucosal resection indications that are excluded from coverage.

    Guideline/assessment-based consideration

    Technologies and tests referenced are supported or evaluated in professional society guidelines and technology assessments; coverage decisions depend on device-specific evidence and guideline recommendations.

    Guideline-supported tests/devices: Tests and devices cited in current society guidelines or technology assessments (for example AGA, ASGE, ASGE Technology Committee, and other assessments) may be considered for coverage when used per guideline indications.per respective guideline/assessment

    See referenced guidance in the policy literature for details (ASGE, AGA, Society of Thoracic Surgeons, Hayes assessments).

    The policy identifies multiple interventions and diagnostic tests as experimental/investigational and not covered for gastroesophageal reflux disease (GERD) or Barrett’s esophagus. Examples specifically listed include EndoCinch, Angelchik prosthesis, Enteryx, Endoscopic Plicator/GERDx systems, Durasphere, Gatekeeper, PMMA microspheres, RefluxStop, EndoStim (LES electrical stimulation), antireflux mucosal interventions (ARMS/ARMA), argon plasma coagulation, cryotherapy, laser therapy, confocal laser endomicroscopy (pCLE), WATS-3D, TissueCypher, capsule endoscopy of the esophagus, and various genetic/methylation/microRNA tests when used for diagnosis or treatment of GERD or Barrett’s esophagus.

    Polymer injection and implantation techniques are described as not supported by sufficient evidence and associated with safety concerns. The policy notes that Enteryx procedure kits were recalled by the FDA after reports of serious adverse events including death, and that devices/techniques such as the Gatekeeper system and PMMA microspheres are not FDA-approved; these factors support classification of these polymer injection/implantation approaches as experimental and not covered.

    Specific CPT codes for endoscopic mucosal resection and ablation are explicitly identified as not medically necessary when billed for the GERD indications listed in this policy. The codes called out are 43211, 43229, 43254, and 43270 and are designated not medically necessary for the GERD diagnoses enumerated.

    The policy states that procedures billed for use with specific injection, implantation, plication, or adjunctive diagnostic technologies (for example, Gatekeeper, Enteryx, PMMA beads, Duraspheres, EndoCinch/Endoscopic Plication systems, cryo or laser ablation techniques, and optical endomicroscopy) are not covered when performed for GERD or Barrett’s esophagus unless specifically listed as covered elsewhere. Unlisted codes submitted for these treatments require explanatory documentation and are considered not medically necessary when used for excluded therapies.

    Early-generation or experimental endoscopic implantation and plication techniques (including some endoluminal gastroplication and ARMI approaches) have limited randomized, sham-controlled trial evidence and inconsistent long‑term outcomes; the policy therefore considers these early feasibility or experimental methods as investigational and not routinely covered given heterogeneous results and potential higher procedural risks.

    No additional explicit coverage exclusions beyond those enumerated elsewhere in the policy are provided in the referenced Medicare/administrative update; the document notes an editorial addition regarding Medicare CLFS designation for certain advanced laboratory tests but does not itself add new not‑covered items.

    The policy groups endoscopic suturing, implantation of inert polymers, polymer injection/implantation techniques, and named device/procedure systems among those considered experimental/investigational and not medically necessary for GERD or Barrett’s esophagus. Examples include EndoCinch, Enteryx, Gatekeeper, PMMA beads, Durasphere implants, and other similar technologies; the policy cites insufficient comparative outcome data and safety concerns as the basis for this stance.

    Anti‑reflux mucosal interventions (ARMS/ARMA) are described as investigational with higher reported procedural morbidity (stricture, bleeding, perforation) compared with some alternatives and lacking endorsement in current society guidelines; similarly, polymer injection/implantation procedures are not supported by sufficient safety and effectiveness data (including recalled Enteryx), and are therefore considered not medically necessary.

    The policy reiterates that CPT codes 43211, 43229, 43254, and 43270 are not medically necessary when billed for the GERD diagnoses listed, and that several other procedure codes (including codes for submucosal injection or optical endomicroscopy when used for excluded technologies) are explicitly listed as not covered.

    Unlisted procedure and miscellaneous codes billed for GERD or Barrett’s esophagus treatments that correspond to procedures the policy designates as not medically necessary or not covered require explanatory notes and supporting documentation; absent appropriate justification, such unlisted codes are considered not medically necessary.

    The literature cited in the policy describes that some endoluminal gastroplication and other early endoscopic plication approaches demonstrated inconsistent long‑term outcomes or long‑term failure in certain series; these outcome patterns are among the reasons such procedures may be treated as not medically necessary in the absence of stronger, durable evidence.

    The document includes multiple references and evidence citations (systematic reviews, technology assessments, randomized and prospective studies) supporting policy positions on diagnostic adjuncts and device therapies; these reference lists do not by themselves enumerate additional not‑covered items but underpin the policy’s evidence-based exclusions and coverage designations.

    Coding and Billing

    WATS-3D — diagnostic adjunctmixed
    not specifiedWATS-3D adjunctive sampling and pathology (device/service described; no explicit CPT/HCPCS codes provided in this section)
    Endoscopic/device anti-reflux proceduresmixed
    not specifiedEndoscopic plication/suturing devices and ARMI procedures (TIF/EsophyX, GERDx, ARMS, ARMA) — device/procedure descriptions without explicit billing codes in this section
    Confocal Laser Endomicroscopymixed
    not specifiedConfocal laser endomicroscopy (pCLE/Cellvizio) — adjunct imaging during endoscopy; no explicit CPT/HCPCS codes provided here
    Implantable anti-reflux devicesmixed
    not specifiedRefluxStop implant (implantable non-encircling anti-reflux device) — device described; no billing codes listed
    ICD-10 Codes that may support medical necessity (GERD)ICD-10
    K20.8xOther esophagitis
    K20.9xEsophagitis, unspecified
    K21.0xGastro-esophageal reflux disease with esophagitis
    K21.9Gastro-esophageal reflux disease without esophagitis
    ICD-10 Codes that may support medical necessity (Barrett's esophagus)ICD-10
    K22.710Barrett's esophagus with low grade dysplasia
    K22.711Barrett's esophagus with high grade dysplasia
    K22.719Barrett's esophagus with dysplasia, unspecified
    Covered CPT Codes (limited to GERD dxs listed)CPTCovered
    43210Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete (when billed for EsophyX System)
    43257Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia (when billed for Stretta System)
    CPT/HCPCS Codes listed as not medically necessary for GERD OR associated with Barrett's esophagus treatmentsmixedNot Covered
    43211Esophagoscopy, flexible, transoral; with endoscopic mucosal resection
    43229Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s)
    43254Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection
    43270Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s)
    96570Photodynamic therapy by endoscopic application of light; first 30 minutes
    96571Photodynamic therapy by endoscopic application of light; each additional 15 minutes
    J9600Injection, porfimer sodium, 75 mg
    Sphincter augmentation placement/removalCPT
    43284Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed
    43285Removal of esophageal sphincter augmentation device
    Diagnostic services (motility and pH/impedance testing)CPT
    91010Esophageal motility (manometric study) with interpretation and report
    91013Esophageal motility study with stimulation or perfusion
    91020Gastric motility (manometric) studies
    91022Duodenal motility (manometric) study
    91030Esophagus, acid perfusion (Bernstein) test for esophagitis
    91034Gastroesophageal reflux test; with nasal catheter pH electrode placement
    91035Gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement
    91037Esophageal function test with nasal catheter intraluminal impedance electrode(s); recording
    91038Esophageal function test with nasal catheter intraluminal impedance electrode(s); prolonged (greater than 1 hour, up to 24 hours)
    91040Esophageal balloon distension study, diagnostic, with provocation when performed
    Sphincter augmentation CPT CodesCPTCovered
    43284Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed. Prior authorization required.
    43285Removal of esophageal sphincter augmentation device. No prior authorization.
    Diagnostic manometry and reflux testing CPT CodesCPT
    91010Esophageal motility (manometric study of the esophagus and/or gastroesophageal junction) study with interpretation and report
    91013Esophageal motility study with stimulation or perfusion (list separately)
    91020Gastric motility (manometric) studies
    91022Duodenal motility (manometric) study
    91030Esophagus, acid perfusion (Bernstein) test for esophagitis
    91034Gastroesophageal reflux test with nasal catheter pH electrode(s) placement
    91035Gastroesophageal reflux test with mucosal attached telemetry pH electrode placement
    91037Esophageal function test with nasal catheter intraluminal impedance electrode(s) placement
    91038Esophageal function test with nasal catheter intraluminal impedance electrode(s); prolonged (>1 hour up to 24 hours)
    91040Esophageal balloon distension study, diagnostic, with provocation when performed
    Molecular and algorithmic pathology (U-codes)HCPCS
    0108UTissueCypher: Whole slide-digital imaging, morphometric analysis, immunolabeling of 9 protein biomarkers and morphology, algorithm reported as risk of progression (covered for Medicare only)
    0114UVIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus (Prior authorization required)
    0398UP16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR on FFPE tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer (Prior authorization required)
    0506UEsophageal cells DNA methylation analysis by NGS of at least 89 DMRs, algorithm reported as likelihood for Barrett's esophagus (Prior authorization required)
    Procedures listed as not coveredCPTNot Covered
    43201Esophagoscopy, flexible, transoral; with directed submucosal injection(s) (when billed for Gatekeeper, Enteryx, PMMA beads, Duraspheres or other GERD/BE treatment not listed as covered) - Not covered
    43206Esophagoscopy, flexible, transoral; with optical endomicroscopy - Not covered
    43210EGD; with esophagogastric fundoplasty (when billed for EndoCinch, Endoscopic Plication System) - Not covered
    43229Esophagoscopy, with ablation of tumor(s)/lesion(s) (when billed for cryo or laser ablation techniques) - Not covered
    43236EGD with directed submucosal injection(s) (when billed for Gatekeeper, Enteryx, PMMA beads, Duraspheres or other GERD/BE treatment not listed as covered) - Not covered
    43252EGD with optical endomicroscopy - Not covered
    43254EGD with endoscopic mucosal resection - Not covered
    WATS-3D / pathology codesCPT
    88104Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation (WATS-3D)
    88305Level IV - Surgical pathology, gross and microscopic examination (WATS-3D)
    88312Special stain including interpretation and report; Group I for microorganisms
    88361Morphometric analysis, tumor immunohistochemistry, quantitative or semiquantitative, per specimen, each single antibody stain procedure; using computer-assisted technology
    ICD-10 and unlisted procedure codesmixed
    K22.710Barrett's esophagus with low grade dysplasia
    K22.711Barrett's esophagus with high grade dysplasia
    K22.719Barrett's esophagus with dysplasia, unspecified
    E1399Durable medical equipment, miscellaneous (Unlisted Codes explanatory notes required)
    L8499Unlisted procedure for miscellaneous prosthetic services
    43289Unlisted laparoscopy procedure, esophagus
    43499Unlisted procedure, esophagus
    43999Unlisted procedure, stomach
    Implantable device systems referencedmixed
    LINX (proprietary device)Magnetic sphincter augmentation system (device-specific implant)
    EndoStim (proprietary device)Lower esophageal sphincter electrical stimulation system (device-specific implant)
    Ancillary diagnostic testsmixed
    TissueCypherTissue systems pathology assay for Barrett's esophagus risk stratification (molecular test)
    WATS-3DWide-area transepithelial sampling with 3D computer-assisted analysis (adjunctive sampling)
    LINX (MSA) age eligibility
    Age range for LINX18 - 74 years
    ContextSpecified as an eligibility criterion for Magnetic Sphincter Augmentation (LINX)
    Source noteListed under LINX eligibility requirements in policy clinical criteria
    LINX (MSA) BMI requirement
    BMI threshold for LINX≤ 35
    RelevanceBMI ≥ 35 is listed as a contraindication for several endoscopic anti-reflux procedures (including TIF) and LINX eligibility requires BMI ≤ 35
    DocumentationBMI must be documented as part of prior authorization/medical necessity evaluation
    Hiatal hernia size limits (TIF vs LINX)
    Hiatal hernia size limitsTIF: ≤ 2 cm; LINX: < 3 cm
    TIF detailTIF indicated for hiatal hernias ≤ 2 cm (TIF 2.0 constructs valve and is intended for hernias ≤ 2 cm)
    LINX detailLINX eligibility requires hiatal hernia < 3 cm as determined by endoscopy
    LINX objective pH testing requirement
    pH criteria for LINXTotal distal ambulatory esophageal pH <4 for ≥4.5% of time off GERD medications for at least 7 days
    Testing conditionpH monitoring must be performed off GERD medications for at least 7 days prior to testing
    RoleObjective acid exposure requirement among LINX eligibility criteria
    Hiatal hernia size (plication/TIF)
    Hiatal hernia size for plication/TIF candidacy≤ 2 cm
    ContextTIF/other endoluminal plication platforms are intended for hiatal hernias ≤ 2 cm
    DocumentationHiatal hernia measurement should be determined endoscopically and recorded in preauthorization/operative notes
    Pre-procedure PPI therapy duration
    Minimum duration of PPI therapy> 6 months of PPI therapy
    ContextPersistent symptoms despite PPI for at least 6 months is an eligibility criterion for TIF and was an inclusion criterion in GERDx trial
    DocumentationDuration and response to PPI therapy should be documented for prior authorization and eligibility
    pCLE (probe-based CLE) imaging depth
    pCLE imaging depth (standard probes)0 to 130 micrometers (μm) for the gastrointestinal tract
    pCLE imaging depth (ultra-high-definition probe)55 to 65 micrometers (μm)
    ContextDepth specifications provided for probe-based confocal laser endomicroscopy (Cellvizio) used as an adjunct to HD-WLE
    Prolonged impedance-pH monitoring duration
    Prolonged impedance-pH monitoring durationProlonged monitoring: greater than 1 hour, up to 24 hours
    Codes referencedCPT 91038 describes prolonged impedance-pH monitoring (>1 hour up to 24 hours)
    UseUsed for extended ambulatory reflux testing when clinically indicated
    Use context for TissueCypher and similar tests
    Use context for advanced assaysRisk stratification in Barrett's esophagus or adjunct to histopathology
    TissueCypher specificsWhole-slide digital imaging and multiplex immunolabeling assay reported as a risk score for progression to HGD/EAC
    DocumentationWhen ordering molecular/algorithmic tests, include pathology reports and clinical context to support intended use

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Stretta — Prior Authorization Recommended

    The Stretta radiofrequency procedure (CPT 43257 when billed for the Stretta System) may be considered medically necessary only when the clinical criteria in the policy are met. Prior authorization is recommended to document that patients meet indication requirements (GERD >6 months, objective evidence of pathologic acid exposure or esophagitis/impedance/biopsy evidence, normal esophageal motility on manometry, and failure of appropriate PPI therapy) and that no exclusion criteria are present (e.g., Barrett's esophagus, hiatal hernia >2 cm, esophagitis grade C–D, pregnancy, certain coagulopathies).

    • CPT 43257 — bill when using Stretta System
    • Document ambulatory pH study off medication or endoscopy/impedance/biopsy evidence
    • Document normal esophageal manometry and refractory symptoms on PPI therapy
    Prior Authorization

    Prior Authorization Recommended for Device/Endoscopic Anti‑Reflux Therapies

    Prior authorization is appropriate for device-based endoscopic or implantable anti-reflux therapies to ensure patient selection meets policy criteria and to confirm coverage status. Examples include transoral incisionless fundoplication (TIF/EsophyX/GERDx), magnetic sphincter augmentation (LINX, CPT 43284), EndoStim LES electrical stimulation, and other endoscopic plication or implantation devices. Providers should submit objective testing and documentation (see documentation callouts) to support medical necessity before scheduling procedures.

    • Common devices: EsophyX/TIF, GERDx, LINX (CPT 43284), EndoStim (investigational)
    • Submit prior authorization request with objective testing and prior therapy details
    • Individual case review may be required for investigational or promising treatments
    Denial Risk

    Procedures (e.g., TIF, Stretta, LINX) — Contraindications and Provider Responsibilities

    Procedures such as TIF, Stretta, and LINX require that providers confirm patients meet the policy's inclusion and exclusion criteria prior to performing the procedure. Contraindications (e.g., large hiatal hernia beyond policy thresholds, advanced esophagitis, significant motility disorders, BMI limits, pregnancy, prior relevant surgeries) must be identified and documented; performing procedures when contraindications are present risks denial.

    • Verify hiatal hernia size (TIF typically ≤2 cm; LINX <3 cm per policy)
    • Confirm esophagitis grade is within allowable range (e.g., Stretta requires A–B; exclude C–D)
    • Document absence of excluded comorbidities (achalasia, scleroderma, active ulcer disease, etc.)
    Billing Rule

    Billing with Supported GERD Codes — Use Covered CPTs and Explanatory Notes for Unlisted Codes

    Claims billed with CPT codes that are not within the policy's listed covered codes for GERD therapies may be denied or considered not medically necessary. Use the specific covered CPT/HCPCS codes when billing for endoscopic anti-reflux procedures and include supporting documentation. Unlisted or misc codes require explanatory notes.

    • Covered: CPT 43210 (EsophyX/TIF when billed appropriately), CPT 43257 (Stretta when billed appropriately), CPT 43284 (LINX placement — prior auth required)
    • Not medically necessary: CPTs 43211, 43229, 43254, 43270 when billed for non‑covered GERD treatments
    • Unlisted codes (e.g., 43289, 43499, 43999, L8499, E1399) must be accompanied by explanatory documentation and may be denied if used for treatments listed as not medically necessary
    Denial Risk

    Denial Risk — Not‑Covered Procedures

    Procedures and techniques listed in the policy as not covered (for example, polymer injection/implantation techniques such as Enteryx™, Gatekeeper™, PMMA implantation, certain cryo or laser ablation approaches when billed for GERD/BE treatment) are not covered. Claims for these services are at high risk for denial.

    • Not covered examples: Enteryx, Gatekeeper, PMMA beads, EndoCinch when billed as specified in policy
    • Directed submucosal injections or optical endomicroscopy billed for non‑covered GERD/BE treatments will be denied
    Denial Risk

    Evidence‑Dependent Coverage Risk — Investigational or Early‑Phase Therapies

    Some endoscopic and implantable therapies have evidence limitations or are described as investigational or early-feasibility. Requests for such procedures may be denied unless an individual case review supports coverage based on promising but investigational data; prior plan approval is required for exceptions.

    • Examples with limited evidence: EndoStim (LES electrical stimulation) — investigational in the U.S.; various ARMS/ARMA techniques have emerging but heterogeneous data
    • Individual case review is available for investigational/experimental treatments when prior approval is obtained
    Prior Authorization

    Prior Authorization — Mixed Requirements and Operational Notes

    The policy does not explicitly require prior authorization for every listed procedure, but prior authorization is required or recommended in multiple cases (see CPT 43284 and laboratory U‑codes). When prior authorization is required, the provider must submit documentation showing medical necessity. Refer to the Priority Health Provider Manual and Evicore guidelines for authorization pathways.

    • CPT 43284 (LINX placement) — prior authorization required
    • Selected molecular U‑codes (e.g., 0114U, 0398U, 0506U) — prior authorization required
    • Check Priority Health Prism → Authorizations → Authorization Criteria Lookup for Evicore guidance
    Documentation Required

    Required Documentation — Objective Testing and Therapy History

    Documentation submitted with prior authorization requests or claims must include objective testing results and relevant clinical information to support medical necessity for device‑based or endoscopic anti‑reflux interventions.

    • Endoscopy findings (e.g., hiatal hernia size, esophagitis grade)
    • Ambulatory pH study performed off GERD medications (percent time pH <4)
    • Esophageal manometry results demonstrating motility and sphincter relaxation
    • History of PPI therapy duration and response (typically ≥6 months or twice‑daily dosing as indicated)
    Documentation Required

    WATS‑3D Adjunctive Documentation

    When WATS‑3D is used adjunctively during endoscopy, include standard forceps biopsy results and clearly state the indication (screening, diagnosis, or surveillance). Documentation should specify whether WATS‑3D sampling was adjunctive to targeted and/or four‑quadrant biopsies and include pathology outcomes.

    • Indication for adjunctive use (screening, diagnosis, surveillance)
    • Copy of concurrent forceps biopsy results and pathology report
    • Statement that WATS‑3D was performed adjunctively (not as a replacement)
    Documentation Required

    Plication Candidate Documentation (TIF/GERDx)

    For candidacy for endoluminal plication procedures (e.g., TIF, GERDx), document prior duration and response to PPI therapy, objective acid exposure, hiatal hernia size (≤2 cm when applicable), and normal esophageal motility. These elements are critical for prior authorization and coverage determination.

    • PPI therapy: duration (≥6 months) and response
    • Ambulatory pH/impedance results showing pathologic reflux
    • Hiatal hernia size documented by endoscopy or imaging (≤2 cm for many plication devices)
    • Esophageal manometry confirming normal peristalsis and sphincter relaxation
    Documentation Required

    WATS‑3D Documentation — Clinical Use and Reporting

    When WATS‑3D is ordered, include the indication (surveillance or screening), prior biopsy history, and whether WATS‑3D is being used adjunctively to forceps biopsy. Provide the pathology report and any relevant follow‑up plans to support medical necessity.

    • Indication and prior biopsy results
    • Pathology reports from WATS‑3D and forceps biopsies
    • Description of how results will impact surveillance or management
    Note

    Medicare CLFS Designation Note

    Some advanced diagnostic molecular or pathology tests described in this policy may meet Medicare criteria as Advanced Diagnostic Laboratory Tests under the Clinical Laboratory Fee Schedule (CLFS). Providers should note Medicare designation implications on claims and follow applicable CLFS billing guidance.

    • Examples include select U‑codes listed under Prior Authorization Required (0114U, 0398U, 0506U)
    • If Medicare ADLT designation applies, follow CLFS billing and documentation requirements

    Definitions and Device/Procedure Descriptions

    Stretta — procedure definition
    Stretta definitionRadiofrequency thermal energy delivered to the lower esophageal sphincter (LES) via endoscopically placed needles intended to remodel tissue and reduce transient LES relaxations
    Mechanism noteProposed effects include scarring, neurolysis, or heat-induced collagen contraction resulting in reduced tLESRs and improved LES compliance
    Clinical placementReviewed as the Stretta System in policy and considered an RF thermal energy approach to GERD management
    Transoral Incisionless Fundoplication (TIF) — definition
    TIF definitionEndoluminal full-thickness plication (e.g., EsophyX) that constructs a valve at the gastroesophageal junction to reduce reflux; intended for hiatal hernias ≤ 2 cm
    TIF 2.0 specificsCreates a 3-cm, 270° valve using 12–23 fasteners (TIF 2.0)
    Clinical roleMinimally invasive alternative to surgical fundoplication for selected patients with persistent GERD
    Magnetic Sphincter Augmentation (LINX/MSA) — definition
    LINX / Magnetic Sphincter Augmentation definitionAn implantable magnetic device wrapped around the LES to augment sphincter competence; eligibility requires defined age, BMI, pH, motility, hiatal hernia, and symptom-response criteria
    Prior authorization notePlacement (CPT 43284) requires prior authorization per policy coding and authorization sections
    ContraindicationsIncludes metallic implants/pacemakers, scleroderma, significant motility disorders, pregnancy, allergy to device materials, and prior anti-reflux surgery
    TIF 2.0 — procedural details
    TIF 2.0 technical detailTransoral incisionless fundoplication creating a 3-cm, 270° gastroesophageal valve using 12–23 fasteners
    Intended effectConstructs a valve to reduce reflux and narrow the gastroesophageal junction
    Comparative noteTIF 2.0 considered most comparable to laparoscopic Nissen fundoplication among endoluminal approaches
    ARMI (ARMS/ARMA) — definition and stance
    ARMI definitionAntireflux mucosal interventions (ARMS/ARMA) use mucosectomy or mucosal ablation to induce scarring/contraction at the gastroesophageal junction to augment the antireflux barrier
    Evidence summaryMeta-analyses report reductions in acid exposure and clinical success rates, but study heterogeneity and risk of complications (stricture, bleeding, perforation) persist
    Coverage stanceConsidered investigational/not medically necessary in policy due to limited guideline endorsement and safety concerns
    WATS-3D — definition and evidence context
    WATS-3D definitionWide-area transepithelial sampling with computer-assisted 3D analysis using a brush biopsy as an adjunct to forceps biopsies to detect Barrett's esophagus and dysplasia
    Intended usePerformed during endoscopy as an adjunct to standard 4-quadrant biopsies for screening, diagnosis, or surveillance
    Evidence noteStudies show increased detection when used adjunctively, but stand-alone use does not consistently outperform standard forceps biopsies
    Confocal Laser Endomicroscopy (CLE) / pCLE — definition
    Confocal Laser Endomicroscopy (CLE) / pCLE definitionEndoscopic technique using a low-power blue laser (488 nm) and fluorescent contrast (topical or IV fluorescein) with a probe advanced through the endoscope to obtain high-resolution microscopic images; adjunct to HD-WLE
    Operational noteImages are acquired in contact with mucosa; procedure adds approximately 5–20 minutes to endoscopy
    LimitationsLimited viewing area and imaging depth; standardization of classification systems remains a challenge
    TissueCypher Barrett's Esophagus Assay — definition
    TissueCypher — assay descriptionImage analysis and biomarker-based test assessing 15 features from 9 protein biomarkers and morphologic features to generate a risk score for 5-year progression to HGD or esophageal adenocarcinoma
    Intended populationPatients with nondysplastic BE, indefinite for dysplasia, or low-grade dysplasia
    Coverage noteTissueCypher (0108U) noted as covered for Medicare; other molecular U-codes may require prior authorization
    TissueCypher and related molecular U-codes
    TissueCypher coverage and coding0108U describes whole-slide digital imaging and multiplex immunolabeling algorithm reported as risk of progression to high-grade dysplasia or cancer (noted as Medicare-covered)
    Other U-codes0114U, 0398U, 0506U describe methylation/NGS-based assays and require prior authorization per policy
    DocumentationOrdering clinicians should include pathology reports and clinical context for risk stratification use

    BACKGROUND: Gastroesophageal reflux disease (GERD) results from impaired antireflux mechanisms including lower esophageal sphincter (LES) dysfunction and alterations of the gastroesophageal junction anatomy, and may be exacerbated by increased intra‑gastric pressure. Initial management typically includes lifestyle modification and pharmacologic therapy (commonly proton pump inhibitors). Patients with persistent, medically refractory symptoms or objective evidence of pathologic reflux despite optimized medical therapy may be considered for procedural options such as surgical fundoplication, endoscopic plication (TIF/EsophyX), radiofrequency (Stretta), or magnetic sphincter augmentation (LINX); however, many emerging endoscopic implantation and diagnostic technologies remain investigational pending stronger evidence and guideline endorsement.

    Policy Revision History

    2026-05committee_reviewLatest

    Policy reviewed by committee (entry listed among historical past committee review dates).

    2026-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2025-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2024-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2023-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2022-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2021-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2020-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2019-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2018-11committee_review

    Policy reviewed by committee (historical past committee review date).

    2017-11committee_review

    Policy reviewed by committee (historical past committee review date).

    2016-11committee_review

    Policy reviewed by committee (historical past committee review date).

    2016-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2015-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2014-05committee_review

    Policy reviewed by committee (historical past committee review date).

    2013-04committee_review

    Policy reviewed by committee (historical past committee review date).

    2012-04committee_review

    Policy reviewed by committee (historical past committee review date).

    2011-04committee_review

    Policy reviewed by committee (historical past committee review date).

    2010-04committee_review

    Policy reviewed by committee (historical past committee review date).

    2010-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2009-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2008-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2007-12committee_review

    Policy reviewed by committee (historical past committee review date).

    2006-12committee_review

    Policy reviewed by committee (historical past committee review date).

    2006-02committee_review

    Policy reviewed by committee (historical past committee review date).

    2005-12committee_review

    Policy reviewed by committee (historical past committee review date).

    2005-01committee_review

    Policy reviewed by committee (historical past committee review date).

    2004-02committee_review

    Policy reviewed by committee (historical past committee review date).

    PRIOR AUTHORIZATION: The referenced sections do not introduce any new, explicit prior authorization requirements beyond those already stated elsewhere in the policy. Where prior authorization is required for specific procedures or molecular U‑codes the policy identifies those requirements in other sections; no additional prior authorization rules are specified in these chunks.